High-Sensitivity ESR1 Detection by Digital PCR in Metastatic Breast Cancer Research Samples: From Analytical Validation to Potential Clinical Applications

The session will provide practical insights for pathologists, molecular biologists, and laboratory professionals interested in applying digital PCR technologies for ESR1 research and assay workflow optimization.

November 3, 2026

The Pathologist

1

ESR1 mutations are significant in acquired resistance to endocrine therapy in HR-positive/HER2-negative metastatic breast cancer.
2

Liquid biopsy is essential for treatment decisions and monitoring disease evolution through circulating tumor DNA (ctDNA).
3

Digital PCR (dPCR) provides high sensitivity for detecting low-frequency ESR1 mutations with rapid turnaround times.
4

A European multicenter study demonstrated the reproducibility and reliability of dPCR-based ESR1 testing across laboratories.
5

The session offers insights for professionals on applying digital PCR technologies for ESR1 research and assay optimization.

High-Sensitivity ESR1 Detection by Digital PCR in Metastatic Breast Cancer Research Samples: From Analytical Validation to Potential Clinical Applications

1

2

3

4

5

Original Source(s)

High-Sensitivity ESR1 Detection by Digital PCR in Metastatic Breast Cancer Research Samples: From Analytical Validation to Potential Clinical Applications

Related Content

Why Better Care Needs Better Connections

ASCP 2026: When Disease Mimics IBD

FDA, CMS target gene therapy barriers